Clinical Trials Logo

Clinical Trial Summary

This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance and/or uncontrolled hypertension


Clinical Trial Description

This Phase 3 study involves two phases, an open-label (OL) phase and a randomized-withdrawal (RW) phase. Patients will dose-escalate in 100 mg increments to a target dose of 400 mg orally once daily during the open-label phase. Patients will remain on open-label treatment until week 22 at which time they will be evaluated for the randomized-withdrawal phase based on pre-defined hyperglycemia and hypertension response criteria. Eligible patients will then be randomized to receive either relacorilant or placebo at a 1:1 ratio for 12 weeks. Patients who do not meet the criteria for randomization will end treatment and may be eligible to roll over into an extension safety study. Patients who complete the randomized-withdrawal phase of the study may also be eligible to roll over into an extension study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03697109
Study type Interventional
Source Corcept Therapeutics
Contact
Status Completed
Phase Phase 3
Start date November 15, 2018
Completion date April 15, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT06050057 - Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Recruiting NCT05881005 - NAC- NAFLD And Cushing N/A
Recruiting NCT00669266 - Adrenal Tumors - Pathogenesis and Therapy
Terminated NCT03379363 - Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
Recruiting NCT06008184 - Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
Recruiting NCT05911620 - Evaluation of the Severity of Hepatic Fibrosis by Magnetic Resonance Elastography in the Diagnosis of Endogenous Hypercorticism N/A
Completed NCT02934399 - Dynamic Hormone Diagnostics in Endocrine Disease
Recruiting NCT04045015 - Liquorice and Salivary Cortisol N/A
Recruiting NCT05804669 - A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome Phase 1/Phase 2
Enrolling by invitation NCT03474237 - A Prospective Cohort Study for Patients With Adrenal Diseases
Recruiting NCT03343470 - The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS)
Recruiting NCT03364803 - Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Terminated NCT02001051 - Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism Phase 2
Enrolling by invitation NCT03604198 - Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Phase 2
Completed NCT05347979 - Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants Phase 1
Recruiting NCT01382420 - Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma N/A
Completed NCT00001849 - New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome Phase 2
Recruiting NCT06229405 - Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data
Recruiting NCT03211624 - Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome
Terminated NCT05456997 - Metabolic Myopathy in Endocrinopathy